Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Life-science tools, instruments and laboratory services / Laboratory consumables and reagents / Contract testing and QC consumables for CROs and CDMOs

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Contract testing and QC consumables for CROs and CDMOs

Routine, high-volume single-use inputs (assay kits, plates, plasticware, glassware, columns, general laboratory chemicals) bought by contract research organisations and contract development and manufacturing organisations to run client analytical panels, bioanalytical testing, stability and release QC. Segmented by buyer organisation type (CRO/CDMO) and the job of delivering contracted, price-benchmarked testing output. Excludes discovery assay work (niche 1), scale-up purification development (niche 2), academic research (niche 4) and clinical sample logistics (niche 5).

Market size
$15.6B
$15.6B ($12.5B–$18.7B) · 2026 · Bottom-up
Growth
+6.0%
$20.9B by 2031
Attractiveness
— /100
for B2B sellers
Evidence
Low confidence
5 sources · Bottom-up
Level
Niche
Segmented by
Customer type
Buyers
Contract research organisations (analytical testing, bioanalytical, clinical labs) and CDMO organisations (QC, release testing, stability testing)
Buying centre
Head of laboratory operations or QC laboratory manager owns the technical spec; purchasing handled by a strategic sourcing or indirect-procurement buyer running competitive tenders; quality assurance approves supplier qualification
Buying triggers
  • New multi-year contract award or client panel expansion that adds testing volume
  • Addition of a new assay or analytical platform to the service menu
  • Annual tender cycle and re-bid of framework supply agreements
  • Cost-down and productivity programmes targeting cost per sample or per batch
Pains
  • Extreme price sensitivity: consumables are the largest controllable cost line in a testing laboratory
  • Multi-site and multi-client demand volatility that makes inventory planning and expiry write-off costly
  • Qualification burden when switching vendors, especially for assay reagents and columns
  • Fragmented spend across many small orders with high administrative and logistics overhead
Scores (1–5)
Pain intensity—
Purchasing power—
Reachability—
Growth5

How this was sized

$15.6B ($12.5B–$18.7B) · 2026 · Bottom-up

Parent pool 2026 USD 60.4B (Emergen tools & reagents 2026 USD 109.77B [3] x 55% consumables-and-reagents share assumption; cross-check GVR 2026 USD 202.6B [1] x 30% = USD 60.8B; parent range USD 48-72B). Niche = parent x 26% assumed CRO/CDMO routine testing share = USD 15.7B, rounded to USD 15.6B; range USD 12.5-18.7B (parent range x 26%). Forecast: 15.6 x 1.06^5 = USD 20.9B by 2031, CAGR aligned with the 6.0% tools & reagents CAGR [3] and below the 6.93% Mordor CAGR [2] because routine contract testing volumes are tied to client R&D budgets rather than instrument-driven demand.

Alongside it in Laboratory consumables and reagents

// Sell into Contract testing and QC consumables for CROs and CDMOs

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.